{"id":23777,"date":"2026-03-03T08:58:33","date_gmt":"2026-03-03T08:58:33","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/23777\/"},"modified":"2026-03-03T08:58:33","modified_gmt":"2026-03-03T08:58:33","slug":"emcure-licenses-roches-nephrology-transplant-brands-india-rights-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/23777\/","title":{"rendered":"Emcure licenses Roche\u2019s nephrology, transplant brands India rights, ETPharma"},"content":{"rendered":"<p>                                        <img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"442\" class=\"unveil\" loading=\"eager\" style=\"width:100%;max-height:100%\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/128946632.cms.png\" captionrendered=\"1\" alt=\"\"\/> Mumbai: <a id=\"243232\" type=\"General\" weightage=\"100\" keywordseo=\"Emcure\" source=\"Orion\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/emcure\" rel=\"nofollow noopener\" target=\"_blank\">Emcure<\/a> Pharmaceuticals has in-licenced Swiss pharma major <a id=\"59733\" type=\"General\" weightage=\"20\" keywordseo=\"Roche\" source=\"Orion\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/roche\" rel=\"nofollow noopener\" target=\"_blank\">Roche<\/a>\u2019s nephrology and <a id=\"6385653\" type=\"General\" weightage=\"20\" keywordseo=\"transplant\" source=\"Orion\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/transplant\" rel=\"nofollow noopener\" target=\"_blank\">transplant<\/a> select <a id=\"31174\" type=\"General\" weightage=\"20\" keywordseo=\"brands\" source=\"Orion\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/brands\" rel=\"nofollow noopener\" target=\"_blank\">brands<\/a> India market commercial rights. <\/p>\n<p>The Pune-based drugmaker has inked a distribution agreement with <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/roche\" rel=\"nofollow noopener\" target=\"_blank\">Roche<\/a> to market Mircera and Neorecormo therapies used in in the chronic kidney disease (<a id=\"265103\" type=\"General\" weightage=\"20\" keywordseo=\"CKD\" source=\"Orion\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/ckd\" rel=\"nofollow noopener\" target=\"_blank\">CKD<\/a>), anemia management, and CellCept, an immunosuppressant used in <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/transplant\" rel=\"nofollow noopener\" target=\"_blank\">transplant<\/a> care, across India.<\/p>\n<p><a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/emcure\" rel=\"nofollow noopener\" target=\"_blank\">Emcure<\/a> has not disclosed the deal financial terms.<\/p>\n<p>\u201cRoche\u2019s globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering optimal care to patients across India,\u201d said Satish Mehta, MD and CEO, Emcure Pharmaceuticals. <\/p>\n<p>\u201cThrough Emcure\u2019s strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche\u2019s long-standing innovations in transplant and <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/ckd\" rel=\"nofollow noopener\" target=\"_blank\">CKD<\/a> care,\u201d Rajji Mehdwan, MD and CEO, Roche India added.                    <\/p>\n<p>                                    Published On Mar 2, 2026 at 05:43 PM IST<\/p>\n<p>\n                Join the community of 2M+ industry professionals.<br \/>\n                Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.\n            <\/p>\n<p>                    All about ETPharma industry right on your smartphone! <\/p>\n<p>                        <img decoding=\"async\" loading=\"lazy\" width=\"90\" height=\"90\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/pharma_barcode.png\" alt=\"\"\/>                        <\/p>\n","protected":false},"excerpt":{"rendered":"Mumbai: Emcure Pharmaceuticals has in-licenced Swiss pharma major Roche\u2019s nephrology and transplant select brands India market commercial rights.&hellip;\n","protected":false},"author":2,"featured_media":23778,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[15081,4010,14828,15146,134,14730],"class_list":["post-23777","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-brands","tag-ckd","tag-emcure","tag-india-commercial-rights","tag-roche","tag-transplant"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/23777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=23777"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/23777\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/23778"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=23777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=23777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=23777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}